Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD

NCT06064071 · View on ClinicalTrials.gov ↗

Study Summary

Clinical Study Evaluating Nordlys™ System with Selective Waveband Technology (SWT)® Intense Pulsed Light (IPL) Applicators for Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD).

Interventions

  • DEVICE Nordlys SWT IPL
  • PROCEDURE Meibomian Gland Expression (MGX)
  • DEVICE Sham Nordlys SWT IPL

Study Locations (3)

Florida

  • Center for Excellence in Eye Care — Miami

Massachusetts

  • Candela Institute of Excellence — Marlborough

Other

  • Av. Del Libertador 662, Piso 17, Dept. 42 — Buenos Aires

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2023-09-18
Est. Completion 2025-09
Phase NA

Sponsor

Candela Corporation

6 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06064071

The ClinicalTrials.gov registry entry for NCT06064071 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Candela Corporation, which has 6 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Dry Eye Disease appearing as the primary indexed condition, and to 3 interventions — of which Nordlys SWT IPL is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06064071 reports 3 study locations spanning 3 distinct geographic areas — top geographies include Florida, Massachusetts, Other. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06064071 about?

NCT06064071 is a clinical study titled "Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD". Clinical Study Evaluating Nordlys™ System with Selective Waveband Technology (SWT)® Intense Pulsed Light (IPL) Applicators for Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD).

What is the current status of trial NCT06064071?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2023-09-18. Estimated completion is 2025-09.

What conditions does trial NCT06064071 study?

This clinical trial studies the following conditions: Dry Eye Disease, Meibomian Gland Dysfunction. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06064071?

The interventions under investigation include: Nordlys SWT IPL (DEVICE), Meibomian Gland Expression (MGX) (PROCEDURE), Sham Nordlys SWT IPL (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06064071?

This trial is sponsored by Candela Corporation, which has 6 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06064071 being conducted?

This trial has 3 study locations across Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial